Anemic syndrome in rheumatoid arthritis: Diagnostic approaches and treatment opportunities


Cite item

Full Text

Abstract

Anemia of chronic disease (ACD) is a leading cause of anemic syndrome in patients with rheumatoid arthritis (RA). Enhanced hepcidin production mainly stimulated by excess interleukin-6 levels is a key pathogenetic component of ACD (frequently known as anemia of inflammation). By causing the degradation of the transmembrane protein ferroportin, hepcidin impairs iron metabolism. On the basis of the material of recent publications, the review gives present-day views on the pathogenesis of ACD in RA, approaches to the diagnosis and differential diagnosis of ACD, especially in its concomitance with iron-deficiency anemia, as well as approaches to therapy for the type of anemic syndrome with the complex mechanism for its development.

References

  1. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD, Tanasescu R. Extra-articular Manifestations in Rheumatoid Arthritis. Maedica (Buchar). 2010;5(4):286-291.
  2. Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):907-927.
  3. Al-Ghamdi A, Attar SM. Extra-articular manifestations of rheumatoid arthritis: a hospital-based study. Ann Saudi Med. 2009;29(3):189-193.
  4. Moller B, Scherer A, Forger F, Villiger PM, Finckh A. Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study. Ann Rhem Dis. 2014;73(4):691-696.
  5. Bloxham E, Vagadia V, Scott K, Francis G, Saravanan V, Heycock C, Rynne M, Hamilton J, Kelly CA. Anaemia in rheumatoid arthritis: can we afford to ignore it? Postgrad Med J. 2011;87(1031): 596-560.
  6. Furst DE, Chang H, Greenberg JD, Ranganath VK, Reed G, Ozturk ZE, Kremer JM. Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry. Clin Exp Rheumatol. 2009;27(4):560-566.
  7. Han C, Rahman MU, Doyle MR, Bathon JM, Smolen J, Kavanaugh A, Westhovens R, St Clair EW, Baker D, Bala M. Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol. 2007;34(11):2177-2182.
  8. Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med. 2004;116(Suppl. 7A):50S-57S.
  9. van Santen S, van Dongen-Lases EC, de Vegt F, Laarakkers CM, van Riel PL, van Ede AE, Swinkels DW. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum. 2011;63(12):3672-3680.
  10. Masson C. Rheumatoid anemia. Joint Bone Spine. 2011;78(2): 131-137.
  11. Peeters HR, Jongen-Lavrencic M, Raja AN, Ramdin HS, Vreugdenhil G, Breedveld FC, Swaak AJ. Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Ann Rheum Dis. 1996;55(3):162-168.
  12. Vreugdenhi G, Wognum A.W, van Eijk HG, Swaak AJ. Anemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness. Ann Rheum Dis. 1990;49(2):93-98.
  13. Prouse PJ, Shawe D, Gumpel JM. Macrocytic anaemia in patients treated with sulphasalazine for rheumatoid arthritis. Br Med J (Clin Res Ed). 1986;293(6559):1407.
  14. Ramselaar AC, Dekker AW, Huber-Bruning O, Bijlsma JW. Acquired sideroblastic anaemia after aplastic anaemia caused by D-penicillamine therapy for rheumatoid arthritis. Ann Rheum Dis. 1987;46(2):156-158.
  15. Toyokawa Y, Kingetsu I, Yasuda C, Yasuda J, Yoshida K, Kurosaka D, Yamada A. Pancytopenia, including macrocytic anemia, associated with leflunomide in a rheumatoid arthritis patient. ModRheumatol. 2007;17(5):436-440.
  16. Tsuji T, Yamasaki H, Tsuda H. Successful treatment with cyclosporine for myelodysplastic syndrome with erythroid hypoplasia following rheumatoid arthritis. Rinsho Ketsueki. 2010;51(6):427-432.
  17. Lehmann P, Hartung W, Ehrenstein B, Schölmerich J, Fleck M. Rheumatoid arthritis and autoimmune hemolysis: B-cell depletion for remission induction in a patient with rheumatoid arthritis and cold agglutinin disease. Z Rheumatol. 2010;69(6):557-560.
  18. Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ. 2008;179(4):333-337.
  19. D’Angelo G. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res. 2013;48(1):10-15.
  20. Gangat N, Wolanskyj AP. Anemia of chronic disease. Semin Hematol. 2013;50(3):232-238.
  21. Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87(4):392-400.
  22. Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica. 2013;98(11):1667-1676.
  23. Erin E. Johnson E.E., Wessling-Resnick M. Iron metabolism and the innate immune response to infection. Microbes Infect. 2012;14(3):207-216.
  24. Muñoz M, García-Erce JA, Remacha ÁF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol. 2011;64(4):287-296.
  25. Northrop-Clewes CA, Thurnham DI. Biomarkers for the differentiation of anemia and their clinical usefulness. J Blood Med. 2013;4:11-22.
  26. Skikne BS, Punnonen K, Caldron PH, Bennett MT, Rehu M, Gasior GH, Chamberlin JS, Sullivan LA, Bray KR, Southwick PC. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol. 2011;86(11):923-927.
  27. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352(10):1011-1023.
  28. Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO 3rd, Bathon J. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures — a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Semin Arthritis Rheum. 2009;39(2):123-131.
  29. Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013;52(10):1845-1855.
  30. Song SN, Iwahashi M, Tomosugi N, Uno K, Yamana J, Yamana S, Isobe T, Ito H, Kawabata H, Yoshizaki K. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res Ther. 2013;15(5):R141.
  31. Hashimoto M, Fujii T, Hamaguchi M, Furu M, Ito H, Terao C, Yamamoto K, Yamamoto W, Matsuo T, Mori M, Ohmura K, Kawabata H, Mimori T. Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis. PLos One. 2014;9(5):e98202.
  32. Ni H, Moe S, Myint KT, Htet A. Oral janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib. ISRNRheumatol. 2013;2013:357904.
  33. Cullis JO. Diagnosis and management of anaemia of chronic disease: current status. Br J Haematol. 2011;154(3):289-300.
  34. Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W; ERA-EDTA ERBP Advisory Board. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. 2013;28(6):1346-1359.
  35. Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Moller B. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol. 2001;28(11):2430-2436.
  36. Chen WS, Liu CY, Lee HT, et al. Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients. Clin Rheumatol. 2012;31(3):469-477.
  37. Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, Swaak AJ. Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomized placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis. 1996;55(10):739-744.
  38. Martí-Carvajal AJ, Agreda-Pérez LH, Solà I, Simancas-Racines D. Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis. Cochrane Database Syst Rev. 2013;2:CD000332. doi: 10.1002/14651858.
  39. Jelkman W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 2013;40(5):302-329.
  40. Cullis J. Anaemia of chronic disease. Clin Med. 2013;13(2):193-196.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies